DIPG/High Grade Glioma Relapse / Refractory
DIPG/High Grade Glioma Relapse / Refractory
Showing 11 - 11 of 11 records.
Volitinib in Treating Participants with Recurrent or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma
- Ages: 6 Years to 21 Year
This phase I trial studies the best dose and side effect of volitinib in treating participants with Medulloblastoma, High-Grade Glioma or Diffuse Intrinsic Pontine Glioma that have come or does not respond to treatment. Volitinib may stop the growth of tumor cells by blocking some of the enzymes nee ...More
Contact Us
To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Medulloblastoma New Diagnosis
- Medulloblastoma Relapse / Refractory
- Low Grade Glioma New Diagnosis
- Low Grade Glioma Relapse / Refractory
- DIPG/High Grade Glioma New Diagnosis
- Ependymoma New Diagnosis
- Ependymoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- ATRT
- Craniopharyngioma
- Germ Cell Tumor
- Choroid Plexus Tumor
- All Other Brain and Spinal Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
